Home
About
Product
Product Center
R&D pipeline
Platform
Blog
Company News
Notice
Industry News
Talent
Contact
Contact Information
Online message
News Center
The Beijing "China Pharma Valley" delegation visits Sinorda Pharmaceutical.
Category:
Time:2024-05-13 00:00
This pioneer in immunotherapy has achieved several "firsts" in the history of human cancer treatment.
Time:2024-03-11 09:38
This was the very first wish Steven Rosenberg, just 6 or 7 years old at the time, developed after hearing from his parents about how some of his relatives had lost their lives in wartime massacres. As he grew older, Rosenberg became a surgeon specializing in cancer treatment. After coming into contact with these cancer patients and witnessing the immense suffering they endured, Rosenberg’s compassionate heart was once again stirred—“I want to ease their pain.”
Sinorda Pharmaceutical presented four posters at APDW for discussion.
Time:2023-12-06 09:41
Sinorda Pharmaceutical attended APDW and presented research data on a new drug, X842 Lipid Capsules, spanning from Phase I to Phase III clinical trials.
Sinorda Pharma's Shenzhen roadshow ranked among the top three.
Time:2023-11-28 09:46
Recently, Sinorda Pharma participated in the "BioFunding Easy Enterprise Financing Roadshow," placing third at the third stop held in the Pearl River Delta region.
Sinorda Pharmaceutical and Sanyou Biotech sign a strategic cooperation agreement to deeply advance innovative drug research and development.
Time:2023-08-18 09:49
Sinorda Pharmaceutical has signed a strategic cooperation agreement with Sanyou Biopharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") on an innovative bispecific antibody drug project.
Sinorda Pharmaceutical has formed a strategic partnership with Boteng Biotech to accelerate the development of cell therapy drugs for solid tumors.
Time:2022-04-22 09:54
On April 22, 2022, Sinorda Pharmaceutical entered into a strategic partnership with Suzhou Boteng Biopharmaceutical Co., Ltd. The two companies will establish a long-term, comprehensive strategic alliance focusing on cell therapy drug development, as well as the construction of cell and gene therapy R&D and manufacturing platforms, and international regulatory submissions.